Document is current

Article History

Received: 25 May 2025

Accepted: 8 September 2025

First Online: 25 September 2025

Declarations

:

: César Ferreira has no conflicts of interest. Brett King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator and/or is on a data monitoring committee for Abbvie, AltruBio Inc., Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Meyers Squibb, Concert Pharmaceuticals Inc., Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Novartis, Otsuka/Visterra Inc., Pfizer Inc., Q32 Bio Inc., Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc., and Ventyx Biosciences Inc. He has served on speaker bureaus for Abbvie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. He is a scientific advisor for BiologicsMD. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB. Tiago Torres is an Editorial Board member of Drugs. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed equally to the idea for the article, conception, drafting, and revision of the manuscript. All authors approved the final version of the article.